India has highest number of US FDA approved
facilities than any other country in the world.
In 1980, Indian Pharma exports was at US$
100 milion.
In 2014, Indian Pharma exports is at US$ 15
billion.
It makes sense to own some of the good
Pharma companies in every investment portfolio, given their visibility for
growth.
Following are few companies:
·
SPARC : Sun Pharma Advanced
Research Co
o
Demerged from Parent Sun Pharma
in 2007
o
Undertakes Pharma research and
drug discovery.
o
Business under two segments:
§ New Chemical Entity Research
§ Novel Drug Discovery
o
Operates in 5 Therapeutic areas
: Oncology, Dermatology, Opthalmology, Respiratory and Central Nervious System
o
Successfully signed licencing
deal with group of co in US for its drug
Xelpros, an eye drop. Received US$ 3 million as upfront payment
o
12 products are in various stages
of development.
·
CIPLA
o
Eight Decade (80 year) old
pharma company
o
Over 1500 products manufactured
over 30 facilities in India.
o
Several manufacturing units are
approved by International regulatory agencies like US FDA.
o
Products sold in over 150
countries with key markets being India, South Africa, US and EU.
o
42% revenue from domestic
market.
o
14% revenue from South africa,
8% from North america and 4% in Europe.
o
One of the first to develop and
manufacture APIs in the country with over 200 APIs in the portfolio.
o
Has richly rewarded investors
with bonuses and rights in its 80 year journey.
o
Latest bonus issued in ratio of
3:2 in FY 2007.
·
Glenmark Pharma:
o
Equal focus on Branded
generics, API’s and Research.
o
One of the leading indian
players in discovery of New Chemical Entity and New Biological Entity.
o
3 new NCEs and 4 NBE molecules
are in clinical trial. Each mlecule has potential peak sales opportunity of US$
1 to US$ 3 billion.
o
14 manufacturing facilities in
4 countries and 6 R& D centres
o
API business sells in over 80
counties.
o
In US, over 100 Generic
products are authorized for distribition and 65 applications are pending in
various stages for approval with US FDA
·
Dr Reddys Laboratories
o
Present across pharma value
chain : APIs, Branded formulations, Generic Drugs, Biologics, Speciality products
and NCEs.
o
Present in 25 countries
o
Business in 3 divisions: Global
Generics (81%), Pharma services and APIC’s (18%) and others (1%)
o
It is one of world’s largest
API manufacturer with partnership with leading innovator companies
o
Business contributions: North
America (47%), India (14%), Europe (12%), Russia (12%) and Rest of wORLD (12%).
·
BIOCON:
o
Segments: Biopharma (57.5%),
Research (13.7%), Branded formulations (26.2%) and others (2.6%)
o
Recombinant human insulin :
INSUGEN : sold in over 85 countries.
o
Oral insulin is under
development jointly with Bristol Myers Squibb.
o
Subsidary SYNGENE is recently
listed
·
Torrent Pharma:
o
Reported 75% growth in revenue
in Q1 of FY 15-16.
o
Launch of new products in US
with limited competition.
o
Focus is on Cardio vascular and
CNS.
o
Also present in Gastro,
Diabetology, Anti infective, Pain managemnet, Nephro, Onco, Gynec and
Pediatrics.
o
Acquired Elder pharma in FY
2015
o
Acquired Zyga Pharma in May
2015
·
DIVIS Lab:
o
2nd most popular
pharma co with MF’s which hold 13.91%
o
Derives 87% of revenue from
exports.
o
Holds 39 Drug Master Files
(DMF) with US FDA and 197 EDMFs and 19 certivicates of suitability with various
EU authorities
o
Has filed for 11 patents for
generic products.
o
Has set us 2 wholly owned subsidary
in US and Swizz to market nutraceutical products.
o
In August 2015, issued 1:1
bonus.on completion of 25 years.
·
UNICHEM Labs:
o
MFs hold 12.65% stake in
Unichem.
o
Derives 57.2% revenue from
overseas markets
o
89% revenue from formulations
and 11% from API’s
o
Wholly owned subsidary in UK,
US, Brazil, South Africa and Ireland.
o
Contributions from US markets
doubled in FY 2015
o
Zero debt company
o
Has 4 manufacturing units, of
which 3 has been inspected by US FDA without any critical observations.
·
NATCO Pharma:
o
Headquartered in Hyderabad
o
Incorporated in CY 1981
o
In 2012, became the 1st
company to be granded compulsotry licence to launch Bayer’s patent protected
anti cancer drug Nexavar in India.
o
Products marketed in over 40
countries.
o
Leaderin Oncology segment with 7
manufacturing facilities. : 5 for formulations and 3 for APIs.
o
Domestic formulations
contribute 30%, International : 21%, APIs 31%.
o
Has a portfolio of 35 ANDA
(Abbreviated New Drug Applications) with aggregate market value of US$ 14.8
billion.
o
Another 20 ANDA worth US$ 11.9
billion is under review.
·
STAR: Strides Arcolab
o
Bangalore based
o
Incorporatd in 1990
o
Makes Generics, Branded
Generica and Bio Pharma
o
Known for aggressive M&A
Strategy.
o
Exited Australian market in CY
2012 and reentered in May 2015 by acquiring ASPEN in May 2015.
o
Acquired
§ Shasun Pharma in Sept 2014
§ Bafna in July 2014
o
Speciality product business was
divested to Mylan in December 2013.
o
Businesses divided into 4
segments
§ Pharma Generics
§ Branded Generics
§ Institutional Business
§ Bio Generics
o
One of world’s largest manufacturer
of soft gelatin capsule.
o
Out of the 5 manufacturing
plants, 2 in Bangalore and 1 in Milan, Italy are approved by key global
regulatory authorities including US FDA.
No comments:
Post a Comment